Gastric and Gastroesophageal Junction Adenocarcinoma - China Drug Forecast and Market Analysis to 2024
Gastric and gastroesophageal junction adenocarcinoma (G/GEJAC) represents the majority of gastric cancer cases worldwide. It is the fifth most diagnosed cancer globally, and the third most common cause of cancer death in the world. The major treatments for G/GEJAC are chemotherapy-based, but targeted therapies such as HER2 and angiogenesis inhibitors have been approved and are being added to chemotherapy regimens since 2010 and 2014, respectively.
Although China has the highest number of incident cases of G/GEJAC across the 8MM, the economic situation of the country has been limiting the growth of the whole oncology pharmaceutical market due to the combined effect of low treatment rate and low uptake of expensive targeted therapies. GlobalData expects the growth of this market to be driven by the increasing incidence of the disease in urban populations, increased number of people covered by private health insurance, increased access to branded biologics, and the uptake of pipeline agents.
- Overview of G/GEJAC including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on the key drugs in China including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for the top drugs in China from 2014-2024. - Analysis of the impact of key events as well the drivers and restraints affecting China G/GEJAC market.
Reasons to buy
- Understand and capitalize by identifying products that are most likely to ensure a robust return - Stay ahead of the competition by understanding the changing competitive landscape for G/GEJAC. - Effectively plan your M&A and partnership strategies by identifying drugs with the most promising sales potential - Make more informed business decisions from insightful and in-depth analysis of drug performance - Obtain sales forecast for drugs from 2014-2024 in China.
Our reports have been used by over 10K customers, including:
Testicular Cancer Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Testicular Cancer Global Clinical Trials Review, H2, 2018" provides an overview of Testicular Cancer clinical trials scenario.This report provides top line data relating to the clinical trials on...
Thymic Carcinoma Global Clinical Trials Review, H2, 2018 Summary GlobalData’s clinical trial report, “Thymic Carcinoma Global Clinical Trials Review, H2, 2018" provides an overview of Thymic Carcinoma clinical trials scenario.This report provides top line data relating to the clinical trials on Thymic...